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rteriogenesis, and Diabetes
aradigm Reassessed?*
ichael Simons, MD, FACC
ebanon, New Hampshire
ype II diabetes mellitus is a complex disease with protean
linical manifestations characterized, at its core, by tissue
esistance to insulin. This fundamental abnormality leads to
ncreased circulating insulin levels and concomitant hyper-
lycemia that, in turn, are thought to be responsible for the
umerous metabolic derangements seen in this syndrome.
On the cardiovascular side, diabetes has long been asso-
iated with accelerated atherosclerosis (1). More recently, a
umber of abnormalities associated with disregulation of
eovascularization have also been recognized. These include
bnormally enhanced angiogenesis, defined as capillary ves-
el growth (2), in the retina, leading to diabetic retinopathy
3) and in the vessel wall, potentially producing atheroscle-
otic plaque destabilization (4). At the same time, insuffi-
ient angiogenesis has been implicated in abnormal wound
ealing, leading to diabetic skin ulcers (5). Defective arte-
See page 827
iogenesis, a process of formation or remodeling of arterioles
nd arteries (2), has also been reported in diabetic patients
6–8). Impaired release of endothelial progenitor cells from
he bone marrow (9) and defective function of these cells
10) are other features of diabetes that further contribute to
bnormal neovascularization and increased cardiovascular
isk.
The molecular defects underlying these angiogenic ab-
ormalities have generated much interest but, so far, have
emained elusive. Diabetic patients have been reported to
ave a reduced number of circulating endothelial progenitor
ells, with the extent of reduction directly proportional to
lasma hemoglobin A1c levels (9). There are also reports of
educed vascular endothelial growth factor (VEGF) and
EGF receptors expression in the myocardium of diabetic
atients (11) as well as increased production of an angio-
enesis inhibitor angiostatin induced by hyperglycemia (7).
This set of observations presents a confusing picture that
eems to defy a common molecular mechanism. An impor-
ant study in this issue of the Journal might lay the
*Editorials published in the Journal of American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.
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edicine and Pharmacology and Toxicology, Dartmouth Medical School,
artmouth-Hitchcock Medical Center, Lebanon, New Hampshire.roundwork for unraveling this puzzle. Sasso et al. (12) have
xamined the expression and function of VEGF and its
eceptors in patients with advanced coronary disease under-
oing coronary artery bypass surgery. In an admittedly
omewhat small sample of twenty patients, they demon-
trated increased VEGF expression in the myocardium of
iabetic patients compared with non-diabetic patients,
hereas expression levels of VEGF receptors 1 and 2 (Flt-1
nd Flk-1, respectively) were reduced. Most importantly,
he extent of Flk-1 phosphorylation, a reflection of its
ctivation status, was severely reduced in diabetic patients
ompared with non-diabetic patients. This was associated
ith a reduced activation of serine-threonine protein kinase
kt-1 and endothelial nitric oxide synthase (eNOS), the
rincipal effectors of the VEGF signaling pathway.
These results extend previous observations of abnormal
EGF signaling in diabetic patients first reported by
altenberger et al. (13), who noted that monocytes from
iabetic patients failed to respond to VEGF in a cell
igration assay despite activation of the Flt-1 receptor.
aken together, these two studies suggest that whereas
lt-1 activation under diabetic conditions is normal, Flk-1
ctivation is not. The role of Flt-1 in VEGF signaling
emains controversial. Unlike Flk-1, which is expressed
lmost exclusively in the endothelium and in certain bone
arrow cell populations, including endothelial precursor
ells, Flt-1, in addition to the endothelium, it is expressed in
wide range of mononuclear cells, including monocytes. It
eems to be involved in the regulation of cell migration
ither via an independent signaling pathway or secondary to
lk-1 activation via an intracellular cross-talk or direct
eceptor heterodimerization.
Flk-1 is currently thought to be the principal receptor
nvolved in transmitting VEGF signaling (Fig. 1). It regu-
ates cell proliferation via activation of the extracellular
eceptor kinase (Erk-1/2) and Akt-1, a master regulator of
ell function. Among many Akt-1 activities, two are the
ost crucial in this context: activation of eNOS, thereby
timulating nitric oxide production, a step required for
ndothelial cell proliferation, and inhibition of apoptosis.
he latter VEGF/Akt-1 activity is probably necessary for
he maintenance of the intact vasculature in adult tissues.
We propose, therefore, the following sequence of events
o explain diabetic angiogenic abnormalities (Fig. 2). The
bnormal activation of Flk-1 leads to increased levels of
irculating VEGF in an attempt to compensate for the
erceived deficiency of VEGF signaling. This is similar to
he increase in insulin levels seen in patients with defective
nsulin signaling. High circulating VEGF levels, in turn,
ead to increased permeability of vascular structures
hroughout the body. In the retina, this results in the
ormation of protein-rich exudates containing VEGF that
nduces a local inflammatory response resulting in capillary
prouting (14). A similar process might take place in the
rterial wall, thereby promoting capillary sprouting and
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Editorial Comment September 6, 2005:835–7laque destabilization. At the same time, the lack of Flk-1
ctivation in endothelial cells and abnormal VEGF-
ependent activation of monocytes impair the arteriogenic
esponse that requires monocyte recruitment and monocyte
nd endothelial cell migration and proliferation. In addi-
ion, VEGF/Flk-1 signaling is thought to be required for
one marrow release of circulating endothelial progenitor
ells that might also play a role in arteriogenesis. The
bnormal release of endothelial progenitors will further
educe arteriogenic response.
Although this scheme seems reasonable, many questions
emain unanswered. What is responsible for elevated VEGF
igure 1. Schematic representation of vascular endothelial growth factor
VEGF) signaling in endothelial cells is presented with putative signaling
bnormalities observed in diabetes, indicated by the dotted X symbol. See
ext for details. eNOS  endothelial nitric oxide synthase; Flk-1  VEGF
eceptor-2; Flt-1  VEGF receptor 1; NO  nitric oxide; P  phosphate;
I3K  phosphoinositol-3-kinase.
igure 2. Graphical representation of the proposed paradigm of neovascu
n impaired Flk-1 activation that affects a number of processes thought to
onocyte and endothelial progenitor cell (EPC) recruitment, and EPC reime, decreased VEGF sensing, due to impaired Flk-1 activation, results in in
theroma). AGE  advanced glycosylated end-products; other abbreviations asevels in diabetic patients? What cells or organs serve as
EGF sensors and increase VEGF expression in response
o declining VEGF/Flk-1 signaling? What is the nature of
he intracellular signaling abnormality that inhibits Flk-1
ctivation? What is the nature of the migration defect in
onocytes and endothelial progenitors of diabetic patients?
With a disease as complex as diabetes, other factors are
ikely to be involved as well. Thus, the presence of advanced
lycation end-products might well play an important role in
uppressing arteriogenesis (15). For example, glycation of
irculating growth factors such as fibroblast growth factor
FGF) has been shown to markedly reduce its biological
ctivity, which, in turn, can inhibit VEGF-dependent
ignaling (16). It is also possible that intracellular signaling
efects in diabetes are not limited to VEGF, but include
ther important arteriogenic growth factors such as FGFs,
latelet-derived growth factors, hepatocyte growth factor,
nd placenta growth factor.
Clearly, much research remains to be done, although
hese discoveries have immediate clinical implications, par-
icularly with regard to ongoing trials of therapeutic angio-
enesis (2,17). If defective arteriogenesis in diabetic patients
s, indeed, secondary to a VEGF signaling defect, therapeu-
ic efforts should be directed not at futile attempts to further
ncrease tissue or plasma VEGF levels, but at restoration of
ntracellular signaling, a strategy that will likely require
mall molecule agents.
In summary, the study by Sasso et al. (12) provides yet
nother important piece in a puzzle that is the arteriogenic
efects of diabetes. The emergence of the VEGF (and
erhaps other growth factors) defective signaling paradigm
n diabetes promises to enhance our understanding of
ion abnormalities in diabetes mellitus. Defective VEGF signaling results
volved in arteriogenesis, including endothelial cell growth and migration,
by the bone marrow. As a result, arteriogenesis is impaired. At the samelarizat
be in
leasecreased serum VEGF levels that lead to pathologic angiogenesis (retina,
in Figure 1.
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